Attention-Deficit/Hyperactivity Disorder Medication Utilization Among U.S. Adults Ages 18-64 Years with Commercial Insurance or Medicare: Implications for Design of Inferential Safety Studies

Attention-Deficit/Hyperactivity Disorder (ADHD) pharmacotherapy is increasingly common in the United States (U.S.), but real-world treatment patterns are not well understood. This poster summarizes an analysis that describes baseline characteristics and longitudinal use patterns in U.S. adults starting ADHD stimulant or non-stimulant medication, using administrative claims data from the Sentinel Distributed Database. It was presented at the 2025 ISPE Annual Meeting.